Long-term ALS survival benefit with CNM-Au8 seen in trial analyses

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation - Advantx Pharmaceuticals Inc.

/wp-content/uploads/2023/09/AI-Medic

Top Research Stories of 2021 – ALS Society of Canada

Frontiers New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022

Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials, Journal of Nanobiotechnology

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. - Abstract - Europe PMC

CLENE REPORTS SIGNIFICANTLY IMPROVED SURVIVAL BENEFIT OF 19.3 MONTHS AND SIGNIFICANTLY DELAYED CLINICAL WORSENING IN RESCUE-ALS OPEN-LABEL EXTENSION TWO YEAR FOLLOW-UP

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension - eClinicalMedicine

Clene: Still in the Running for ALS